FASCILIREN Trademark

Trademark Overview

On Monday, December 17, 2018, a trademark application was filed for FASCILIREN with the United States Patent and Trademark Office. The USPTO has given the FASCILIREN trademark a serial number of 88231826. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, July 25, 2022. This trademark is owned by Pfizer Inc.. The FASCILIREN trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use
fasciliren

General Information

Serial Number88231826
Word MarkFASCILIREN
Filing DateMonday, December 17, 2018
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, July 25, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 23, 2019

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, January 8, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10017
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Monday, July 25, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, July 25, 2022ABANDONMENT - NO USE STATEMENT FILED
Tuesday, December 28, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, December 27, 2021SOU EXTENSION 5 GRANTED
Monday, December 13, 2021SOU EXTENSION 5 FILED
Monday, December 27, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, December 13, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, September 14, 2021ASSIGNED TO EXAMINER
Wednesday, June 16, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 14, 2021SOU EXTENSION 4 GRANTED
Monday, June 14, 2021SOU EXTENSION 4 FILED
Monday, June 14, 2021SOU TEAS EXTENSION RECEIVED
Friday, November 6, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 4, 2020SOU EXTENSION 3 GRANTED
Wednesday, November 4, 2020SOU EXTENSION 3 FILED
Wednesday, November 4, 2020SOU TEAS EXTENSION RECEIVED
Thursday, June 4, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 2, 2020SOU EXTENSION 2 GRANTED
Tuesday, June 2, 2020SOU EXTENSION 2 FILED
Tuesday, June 2, 2020SOU TEAS EXTENSION RECEIVED
Thursday, December 12, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, December 10, 2019SOU EXTENSION 1 GRANTED
Tuesday, December 10, 2019SOU EXTENSION 1 FILED
Tuesday, December 10, 2019SOU TEAS EXTENSION RECEIVED
Wednesday, November 27, 2019APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, November 27, 2019ASSIGNED TO LIE
Tuesday, November 26, 2019TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Tuesday, June 18, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 23, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 23, 2019PUBLISHED FOR OPPOSITION
Wednesday, April 3, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 12, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, March 5, 2019ASSIGNED TO EXAMINER
Tuesday, January 8, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, December 20, 2018NEW APPLICATION ENTERED

Related Keywords

fasciliren preparations disorders pharmaceutical dysfunction treatment liver erectile blood viral urological